Sodium-glucose cotransporter-2 inhibitors: A potential novel treatment for Lafora disease?

Sodium-glucose cotransporter-2 inhibitors: A potential novel treatment for Lafora disease?

Bibliographic Details
Main Authors:	Paola Imbrici, Giuseppe d’Orsi, Massimo Carella, Orazio Nicolotti, Annamaria De Luca, Cosimo Damiano Altomare, Antonella Liantonio
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Pharmacological Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1043661823003687

Similar Items

Electro-clinical features and management of the late stage of Lafora disease
by: Giuseppe d'Orsi, et al.
Published: (2022-10-01)

Association of CSF and PET markers of neurodegeneration with electroclinical progression in Lafora disease
by: Giuseppe d'Orsi, et al.
Published: (2023-06-01)

Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach
by: Marco Mele, et al.
Published: (2023-06-01)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
by: A. M. Mkrtumyan, et al.
Published: (2021-09-01)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions
by: Habib Yaribeygi, et al.
Published: (2023-01-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
by: Xiaoya Sun, et al.
Published: (2022-12-01)

An exanthematous drug eruption with sodium‐glucose cotransporter 2 inhibitor
by: Ryu Fukase, et al.
Published: (2024-01-01)

Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
by: Jiangjun Wei, et al.
Published: (2023-04-01)

The Rate of Adverse Events of Sodium-Glucose Cotransporter 2 Inhibitors:
by: Omar Sajdeya
Published: (2023-05-01)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
by: He Sun, et al.
Published: (2023-01-01)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
by: Annamaria Mascolo, et al.
Published: (2023-11-01)

Effectiveness and safety of sodium–glucose cotransporter 2 inhibitors in Asian populations
by: Kyoung Hwa Ha, et al.
Published: (2024-03-01)

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
by: Hidekatsu Yanai, et al.
Published: (2021-04-01)

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
by: Habib Yaribeygi, et al.
Published: (2023-04-01)

Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
by: Shingo Kato, et al.
Published: (2023-04-01)

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
by: Ting-Wei Kao, et al.
Published: (2022-12-01)

Sarcoplasmic Reticulum Ca<sup>2+</sup> Buffer Proteins: A Focus on the Yet-To-Be-Explored Role of Sarcalumenin in Skeletal Muscle Health and Disease
by: Elena Conte, et al.
Published: (2023-02-01)

Use of Sodium–glucose Cotransporter 2 Inhibitors in Patients with Chronic Kidney Disease
by: Ahmed M Alkhunaizi, et al.
Published: (2023-01-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
by: Munteanu Madalina Andreea, et al.
Published: (2023-04-01)

Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
by: Eun Sil Koh, et al.
Published: (2023-08-01)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
by: Shingo Kato, et al.
Published: (2022-10-01)

Promising role of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy
by: Samaneh Zandifar, et al.
Published: (2023-06-01)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
by: Ahmadieh H, et al.
Published: (2017-05-01)

Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
by: Thahesh Tharmaraja, et al.
Published: (2022-04-01)

Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor
by: In-Young Nho, et al.
Published: (2018-12-01)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
by: Juexing Li, et al.
Published: (2022-09-01)

Sodium-glucose cotransporter-2 inhibitors: Moving beyond the glycemic treatment goal
by: Vishal Gupta, et al.
Published: (2017-01-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
by: Al-Anood Al-Shamasi, et al.
Published: (2021-11-01)

Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia
by: Yu Horiuchi, et al.
Published: (2024-03-01)

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
by: Jan P. Kleinjan, et al.
Published: (2024-03-01)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
by: Muhammad Shahzeb Khan, et al.
Published: (2019-11-01)

Physicians’ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors
by: Serge A. Jabbour, et al.
Published: (2022-10-01)

Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
by: N. B. Perepech, et al.
Published: (2021-07-01)

Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation
by: Sheng‐Nan Chang, et al.
Published: (2023-05-01)

Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor
by: D. A. Lebedev, et al.
Published: (2020-10-01)

Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor
by: Hyung Ah Jo, et al.
Published: (2023-02-01)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
by: Simes BC, et al.
Published: (2019-10-01)